Aytu BioPharma, Inc.
AYTU · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -8.2% | -18% | 13.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 66.1% | 67.8% | 69.4% | 66.5% |
| EBITDA | $0 | -$0 | $0 | $0 |
| % Margin | 23.6% | -115.1% | 32.7% | 16.2% |
| Net Income | $0 | -$0 | $0 | $0 |
| % Margin | 14.1% | -130.9% | 21.6% | 4.9% |
| EPS Diluted | -0.08 | -2.92 | 0.21 | -0.26 |
| % Growth | 97.3% | -1,490.5% | 180.8% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | $0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | $0 |